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ABSTRACT
RNA interference represents a potent intervention
for cancer treatment but requires a robust delivery
agent for transporting gene-modulating molecules,
such as small interfering RNAs (siRNAs). Although
numerous molecular approaches for siRNA delivery
are adequate in vitro, delivery to therapeutic targets
in vivo is limited by payload integrity, cell target-
ing, efficient cell uptake, and membrane penetration.
We constructed nonviral biomaterials to transport
small nucleic acids to cell targets, including tumor
cells, on the basis of the self-assembling and cell-
penetrating activities of the adenovirus capsid pen-
ton base. Our recombinant penton base chimera con-
tains polypeptide domains designed for noncovalent
assembly with anionic molecules and tumor hom-
ing. Here, structural modeling, molecular dynamics
simulations, and functional assays suggest that it
forms pentameric units resembling viral capsomeres
that assemble into larger capsid-like structures when
combined with siRNA cargo. Pentamerization forms
a barrel lined with charged residues mediating pH-
responsive dissociation and exposing masked do-
mains, providing insight on the endosomolytic mech-
anism. The therapeutic impact was examined on tu-
mors expressing high levels of HER3/ErbB3 that are
resistant to clinical inhibitors. Our findings suggest
that our construct may utilize ligand mimicry to avoid
host attack and target the siRNA to HER3+ tumors by
forming multivalent capsid-like structures.
INTRODUCTION
HER3/ErbB3 promotes the growth of an expanding range
of tumor types (1–13). An increase in its expression is
associated with a worsening prognosis and a more ag-
gressive phenotype that resists current clinical interven-
tions, including inhibitors of the ErbB receptor kinase
axis (1,2,7,14–18). Accordingly, there is growing interest
for the targeting of HER3 in the clinic. Although it con-
tains an inactive kinase domain, making it an impracti-
cal target for signal inhibition (19,20), the increased den-
sity of HER3 on the surfaces of resistant tumor cells pro-
vides a useful biomarker for active targeting of those cells
and a potentially valuable portal for the accumulation of
ErbB-directed therapeutic-loaded nanocarriers. In support,
we have shown that our HER3-homing protein construct,
HPK, mediates the targeted delivery of chemotherapeutic
compounds to trastuzumab (Herceptin)-resistant breast tu-
mors, which display high cell surface densities of HER3
(21). As these tumors can resist conventional tumoricidal
drugs, the targeted delivery of alternative cargo––such as
small interferingRNA (siRNA)––may provide useful thera-
peutic options. The delivery of siRNA via HER3-mediated
targeting has not yet been reported, likely because HER3
is a recently emerging tumor target and corresponding lig-
ands are not widely available or widely explored for direct-
ing therapeutic carriers.
RNA interference (RNAi) offers a powerful gene-
silencing tool for cancer treatment, but in vivo delivery bar-
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riers limit its clinical application (22). In addition to tar-
geting the RNAi to tumor cells, effective in vivo delivery
vehicles must package the RNAi molecules such that they
are protected from nuclease-mediated degradation during
transport and also penetrate the target cells to release the
cargo into the cytoplasm (23,24). Cytoplasmic delivery is es-
sential for selective pairing with and degradation of mRNA
targets (22). Hence, a robust system is needed for in vivo tar-
geted delivery of RNAi. Although lipid-enveloped and bio-
conjugated siRNAs have been extensively explored in pre-
clinical studies (25), many of the existing technologies lack
selective tumor targeting and do not target HER3. Thus, in
the present study, we tested the utility of HPK for directing
RNAi to HER3-dense tumors in vivo.
The potent delivery of nucleic acids by viruses has
inspired the development of virus-derived proteins
(26)––including HPK––for the nonviral transport of thera-
peutics. The proteins comprising the outer shell, or capsid,
of many viruses mediate cell penetration during infection
(27). Viral capsid-derived proteins retain cell-penetrating
activities of whole viruses without infection activity or the
potential for recombination with wild-type viruses (28).
Their use for in vivo non-viral delivery of nucleic acids
may require covalent attachment of chemical moieties to
reduce immune surveillance and protect the cargo from
systemic degradative molecules (26). However, such chem-
ical modifications may alter the function and complicate
vector construction, creating challenges for translation to
the clinic (29). We created viral capsid-derived biocarriers
using a single chimeric fusion construct, HPK, containing
the functions for cargo loading, tumor targeting, and mem-
brane penetration (21). HPK is derived from the adenovirus
(Ad) capsid penton base (PB) protein, which contributes
to membrane penetration and cell entry of the virus during
infection (30–32). The capsid PB has been explored for the
delivery of molecular therapeutics because of its ability
to penetrate the cellular endosomal membrane (32–36)
despite its unclear mechanism for endosomal disruption, or
endosomolysis. The ligand used to target HPK to tumors
is derived from the minimal receptor-binding region of
the ErbB growth factor, heregulin-11 (37). This minimal
ligand specifically recognizes HER3 and induces rapid
endocytosis while reducing heregulin-mediated signaling in
HER3-expressing tumor cells (21). These findings extend to
HER2+ breast tumor cells (38,39) due to the coexpression
and heterodimerization of HER3 and HER2 (20,40–42).
These studies demonstrated that HPK mediates robust
uptake of drug compounds into cells (21) and thus may
bear the features needed for effective transport of siRNA
payloads.
To test HPK as a HER3-targeted biocarrier for systemic
delivery of siRNA to tumors in vivo, we focused on two ma-
jor areas of translational development. First, we used com-
plementary approaches to uncover several key mechanisms
that are crucial for in vivo delivery, including the vaguely
understood mode of endosomolysis by the PB that is essen-
tial for the delivery of nucleic acids (31,33). Here, we used
computational biophysical methods for the structural mod-
eling of HPK in different oligomeric states and then evolved
the HPK structures under physiological conditions using
molecular dynamics (MD) simulations to uncover its influ-
ences on siRNA particle assembly, stability, targeting, and
host recognition, which were then tested in functional as-
says. Second, our assessment of targeted siRNA delivery by
HPK entailed a validation of appropriate mouse models for
interpreting targeting in vivo. As most clinically approved
targeted therapies are specific to human antigens, caution
must be applied when evaluating tumor targeting in rodent
models with human xenografts, which is often disregarded
when nanocarriers are tested for ligand-directed targeting.
Here, we examined the interspecies cross-reactivity of HPK
to determine the extent to which in vivo targeting can be
validly interpreted. We also assessed HPK function in two
different in vivomodels of HER3-expressing cancer, includ-
ing an immune-competent model of triple-negative breast
cancer. HER3+ tumors present clinical scenarios with lim-
ited therapeutic recourse (43); hence, the delivery of siRNA
therapeutics via HER3-mediated targeting may widen the
options available to such cancers.
MATERIALS AND METHODS
Materials
A synthetic ErbB2/HER2 siRNA duplex (RTF primer,
TCTGGACGTGCCAGTGTGAA; RTR primer, TGCT
CCCTGAGGACACATCA) was obtained from Invitrogen
(Carlsbad, CA,USA). Firefly luciferase (Luc) and negative-
control (scrambled [Scr]) siRNAs were obtained from Ap-
plied Biosystems/Ambion. Buffer A comprised Dulbecco’s
modified Eagle’s medium, 20 mM HEPES (pH 7.4), 2 mM
MgCl2 and 3% bovine serum albumin (BSA; in phosphate-
buffered saline [PBS] or H2O).
Cells
All cell lines were obtained from theAmericanTypeCulture
Collection and were maintained at 37◦C with 5% CO2 un-
der mycoplasma-free conditions in complete medium (Dul-
becco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, and 100 g/ml
streptomycin).
Protein production
Recombinant proteins were produced from the pRSET-
A bacterial expression vector, which adds an N-terminal
6× His sequence for metal chelate affinity purification of
the fusion protein. To produce the fusion protein in bac-
teria, 50-ml cultures of Escherichia coli BLR(DE3)pLysS
transformed with the pRSET constructs were grown to
turbidity at 37◦C with vigorous agitation and then ex-
panded to 500-ml cultures that were induced with 0.4 mM
IPTG (isopropyl--D-thiogalactopyranoside) at an optical
density at 600 nm of 0.6–0.8. Three hours later, the cells
were pelleted and resuspended in 5 ml lysis buffer (50
mM NaH2PO4, 50 mM NaCl, pH 8) containing 0.1% Tri-
ton X-100 and 1 mM phenylmethylsulfonyl fluoride. Af-
ter one freeze-thaw cycle, 10 mM MgCl2 and 0.01 mg/ml
DNase I were added, and the lysates were gently agitated
at room temperature (RT) until the viscosity was reduced.
The lysates were then transferred to ice, and 1 M NaCl
and 10 mM imidazole (final concentrations) were added.
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The lysates were clarified by centrifugation at 4◦C, followed
by affinity purification using nickel-charged medium, wash-
ing and eluting with a step gradient of imidazole (ranging
from 20 to 250 mM) in 50 mM NaH2PO4 and 300 mM
NaCl. Fractions containing eluted protein (∼92 kDa) were
buffer exchanged by ultrafiltration in storage buffer (20mM
HEPES [pH 7.4], 150 mM NaCl, 10% glycerol).
Particle formation
The incubation of HPK with siRNA species (4:1 molar ra-
tio) at RT for at least 20 min and then for at least 1 h on
ice with agitation produced complexes we referred to as
HSi. The mixtures were subjected to ultrafiltration using
100Kmolecular-weight-cutoff membranes to isolate assem-
bled particles from unassembled components. The siRNA
concentration in particles was quantified by either ethid-
ium bromide staining after gel electrophoresis in compar-
ison to that of free siRNA of known quantities or by hep-
arin treatment to release siRNA followed by fluorescence
quantification using a nucleic acid binding dye (RiboGreen;
Thermo Fisher Scientific). The protein content was mea-
sured by spectrophotometric absorbance using either the
Bradford method (Bio-Rad dye assay) or measuring the ab-
sorbance at 280 nm.
Structural modeling
Generation of the pentameric HPK structure. For HPK
(also known as HerPBK10) (44), the Her and PBK do-
main structures were based on the following amino acid se-
quences:
Her, ELLPPRLKEMKSQESAAGSKLVLRCETSSE
YSSLRFKWFKNGNELNRKNKPQNIKIQKKPGKSE
LRINKASLADSGEYMCKVISKLGNDSASANITIV
ESNEIITGMPASTEGAYVSSESPIRISVSTEGANTSSS
TSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDL
SNPSRYLCKCQPGFTGARCTENVPMKVQNQEKAE
ELYGGSGGSGS (215 amino acids);
PBK, MRRAAMYEEGPPPSYESVVSAAPVAAAL
GSPFDAPLDPPFVPPRYLRPTGGRNSIRYSELAPLF
DTTRVYLVDNKSTDVASLNYQNDHSNFLTTVIQN
NDYSPGEASTQTINLDDRSHWGGDLKTILHTNMP
NVNEFMFTNKFKARVMVSRLPTKDNQVELKYE
WVEFTLPEGNYSETMTIDLMNNAIVEHYLKVGRQ
NGVLESDIGVKFDTRNFRLGFDPVTGLVMPGVYT
NEAFHPDIILLPGCGVDFTHSRLSNLLGIRKRQP
FQEGFRITYDDLEGGNIPALLDVDAYQASLKDDT
EQGGGGAGGSNSSGSGAEENSNAAAAAMQPVE
DMNDHAIRGDTFATRAEEKRAEAEAAAEAAAP
AAQPEVEKPQKKPVIKPLTEDSKKRSYNLISNDS
TFTQYRSWYLAYNYGDPQTGIRSWTLLCTPDVTC
GSEQVYWSLPDMMQDPVTFRSTRQISNFPVVGAE
LLPVHSKSFYNDQAVYSQLIRQFTSLTHVFNRFP
ENQILARPPAPTITTVSENVPALTDHGTLPLRNSIG
GVQRVTITDARRRTCPYVYKALGIVSPRVLSSRT
FKKKKKKKKKK (581 amino acids).
The Her domain structure was obtained by using the
protein structure prediction server I-TASSER (45), and the
PBK domain structure was built with the SWISS-MODEL
(46) server utilizing the PB structure (PDB 3IZO) (47) as
a template. The structural models did not include the N-
terminal 6 × His tag used for affinity purification. The pen-
tameric PBK structure was built from the monomer struc-
ture, obtained through SWISS-MODEL, using the PDB
1X9T (48) as a template. This pentameric PBK structure
was placed in a water box and relaxed for 100 ns using MD
simulations as described below for the full HPK structure.
Pentamer snapshots were saved at regular intervals, and the
snapshot with the smallest root mean squared deviation of
C atoms between structures was selected as an average
structure. The Her domain structure from I-TASSER was
physically placed near theN-terminal end of the selected av-
erage structure of PBK, avoiding any clashes with the PB,
which resulted in an HPK pentamer structure. This struc-
ture was relaxed in its native environment as described be-
low.
Relaxation of pentameric HPK in a physiological environ-
ment. The above-described structure of HPK was embed-
ded in a water box (using the tleap program that is part of
the AMBER simulation suite (49)) made up of 293 402 wa-
ter molecules with the system size of 247 A˚ × 244 A˚ by
165 A˚ and a total of 941 411 atoms including the protein
and added Cl− ions that neutralize the system. The sim-
ulated system is shown in Supplementary Movie S2. The
pentameric protein structure was relaxed to test its stability
using the following computational protocol, which utilized
the pmemd.cuda (GPU) program from the AMBER simu-
lation suite and the AMBER force field ff14SB to represent
the interatomic interactions and forces. Step 1, the solvent
energy is minimized while keeping protein constrained to
enable the solvent to adjust around the protein; step 2, the
solvent is relaxed for 100 ps using MD simulation at 310 K
temperature and 1 atm, while keeping the protein restrained
to enable the solvent to rearrange especially around the po-
lar exposed residues in the protein and to fill any artificial
holes in the simulation box; step 3, the full system’s energy
is minimized to enable the protein to adjust to the solvent;
step 4, the full system is heated to 310K and equilibrated for
100 ps to enable the full system to adjust to the physiological
temperature; step 5, the full system is equilibrated for 250 ps
to enable the density of the full system to converge; step 6,
the full system is equilibrated for 100 ns, during which time
the system snapshots are saved at regular intervals for subse-
quent analysis of the stability and other features of the sim-
ulated system. The root mean squared deviation of the C
atoms of one structure relative to another structure, mea-
sured from the snapshots to determine the representative
structure, was used to analyze the buried solvent accessi-
ble surface area and the relative size of the pentamer versus
monomer structures. It was also used in the PropKa server
(50) to compute the pKa values of all titratable residues in
the HPK pentamer.
Co-precipitation assay
PBK and HPK fusion proteins (10 g each) containing
6× His tags were prebound to nickel-nitrilotriacetic acid
resin (10 l 50% slurry) in 200 l incubation buffer (50
mM NaH2PO4 [pH 8], 0.1 M NaCl, 5 mM imidazole,
10% glycerol, 0.01% NP-40) for 1 h at 4◦C. Unbound pro-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz900/5588347 by U
C
LA user on 16 O
ctober 2019
4 Nucleic Acids Research, 2019
tein was removed by washing the resin once in incubation
buffer and twice in wash buffer (incubation buffer contain-
ing 0.05MNaCl). [35S]Met-labeled PB produced by in vitro
translation in accordance with the manufacturer’s protocol
(Promega TNT coupled transcription/translation kit) was
added to each mix to achieve a 200-l final volume in wash
buffer and incubated with agitation for 2 h at 4◦C. The resin
was pelleted and washed four times in wash buffer, and the
pelleted resin was resuspended in a mixture of 8 l water
and 8 l SDS-PAGE loading dye. Mixtures were boiled for
5 min, followed by pelleting and loading of supernatants
onto the gel.
Receptor binding
Enzyme-linked immunosorbent assay (ELISA) plate wells
were coated with HER3 peptide at ∼5 g/ml (100 l per
well) overnight at 4◦C in coating buffer (0.1 M NaHCO3,
pH 9.6) and then washed in PBS to remove unbound pro-
tein. The plates were incubated for 1 h at RT in blocking
buffer (3%BSA in PBS). Aspiratedwells then receivedHPK
(∼0.5 g/well) ± preadsorbed HER3 peptide (i.e. peptide
preincubated with HPK at 10× molar excess) in PBS and
were incubated for 1 h at RT with agitation, followed by
washing and processing for immunodetection using an anti-
RGS-His tag antibody (1:1000; Qiagen, MD, USA) and
anti-mouse secondary antibody (1:2000). To analyze HPK
binding after HER3 silencing, 96-well plates were seeded
with 5000 MDA-MB-435 cells 24 h before a HER3 siRNA
pool (product number 1027416; Qiagen) was applied using
standard transfection procedureswith commercial formula-
tions. Briefly, 100 ng of HER3 siRNA or scrambled control
siRNAwas diluted inOpti-MEMmediumand delivered us-
ing Lipofectamine 3000 (Invitrogen) according to the man-
ufacturer’s instructions. Twenty-four hours later, the cells
were treated with 1.5 g of HPK per well diluted in com-
plete medium. HPKwas added to cells on ice for 1 h to pro-
mote binding but not uptake. Cells were then thoroughly
washed with PBS, fixed using 4% PFA, and processed for
immunodetection of HPK and HER3 as described un-
der ‘Immunocytofluorescence/Immunohistofluorescence’.
High-throughput acquisition of HER3 and HPK signals
from each cell (>500 cells per field in three independent
fields per well of triplicate wells) was performed using an
ImageXpress Pico scanner (Molecular Devices).
Cell surface ELISA
Cells were plated at 1 × 104/well unless otherwise indicated
in 96-well plates and maintained for 24 h before washing
with PBS containing 1% MgCl2 and 1% CaCl2 fixing with-
out permeabilization (to detect cell surface proteins only),
and ELISA processing, as described previously (44). The
plates were then processed for crystal violet staining for
normalization according to cell number, as described pre-
viously (51). Cell surface HER3 was detected on human
tumor lines using an antibody that recognizes the extra-
cellular domain of HER3 (Ab105; Pierce-Thermo Fisher,
MA, USA). Mouse HER3 was detected on 4T1 cells and
in specimens using an antibody that cross-reacts with both
human and mouse HER3 (1B2E; Cell Signaling Technolo-
gies). Other receptor levels (ErbB1/HER1, ErbB2/HER2,
and ErbB4/HER4) were detected using respective antibod-
ies described previously (21).
Intracellular trafficking
Cells growing on coverslips in six-well plates were exposed
to HPK or HSi at equivalent protein concentrations (20
g/well) according to our previously established proce-
dures (52). Briefly, cells were treated on ice for 1 h to pro-
mote receptor binding but not internalization, washed to
remove unbound protein, and warmed to 37◦C to pro-
mote synchronized uptake and intracellular trafficking.
Cells were fixed at various time points after warming and
then processed for immunofluorescence identification of
HPK or HSi using an antibody that recognizes the poly-
histidine tag (RGS-His antibody; Qiagen). Antibodies for
RAB7 and EEA1 were purchased from Abcam (ab50533
and ab206860, respectively). Samples were imaged using a
Leica SPE laser scanning confocal microscope. Acquired
images were imported to ImageJ and split into individual
channels. Individual cells in selected channels were delin-
eated, and integrated densities were measured for each se-
lected area.
Immunocytofluorescence/immunohistofluorescence
Cells were fixed and processed for immunocytofluorescence,
as previously described (52). Tissues harvested from mice
were preserved in 4% paraformaldehyde in PBS and then
transferred to 70% ethanol. Tissues were then paraffin em-
bedded, sectioned, and mounted onto slides. The slides
were deparaffinized by incubating in a dry oven for 1 h
and then washing in xylene five times for 4 min each, fol-
lowed by sequential rinses in 100%, 95%, 90%, 80% and
70% ethanol, twice each for 3 min. The slides were then
submerged in water. Epitope retrieval was performed by
incubating the slides for 30 min at 37◦C in 20 g/ml
proteinase K in 10 mM Tris (pH 7.8). Following treat-
ment, the slides were counterstained with 4’,6-diamidino-
2-phenylindole (DAPI; Thermo Fisher) and mounted with
Prolong Antifade (Thermo Fisher). Images of the tissues
were captured using a Leica SPE laser scanning confocal
microscope. Images were analyzed using ImageJ.
Subcellular fractionation
PB and HPK were internalized by MDA-MB-435 cells fol-
lowed by biochemical isolation of cell compartments to as-
sess the subcellular distribution of each protein. Specifically,
cells were detached with 2 mM ethylenediaminetetraacetic
acid (EDTA) in PBS (no trypsin to ensure that cell surface
receptors for each protein remained unmodified) followed
by 3–4 washes in PBS containing Ca2+ andMg2+ to remove
EDTA and resuspension of cells in buffer A containing ∼7
nmol PB or HPK (per 5 × 106 cells). The mixtures were
incubated with agitation for 2 h at 4◦C to allow cell attach-
ment but not internalization, followed by incubation for 2
h at 37◦C to promote synchronized uptake. The cells were
then pelleted, washed, and processed for subcellular frac-
tionation using a Qproteome cell compartment assay kit
(Qiagen), per the manufacturer’s protocol.
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Native PAGE
HPK in storage buffer (20 mMHEPES [pH 7.45], 150 mM
NaCl, 10% glycerol) was distributed into 150-l aliquots at
1.33 g/l, and the pHs were adjusted by mixing with 350
l of storage buffer at titrating pH levels for 30 min at 25◦C
or 37◦C (0.4 g/l final protein concentration). Final pH
values were confirmed using an Oakton pHTestr 50S (Cole-
Parmer). Each sample underwent size filtration to retain
HPK oligomers as previously established (21,44), and was
sustained in its own pH buffer during application to spin
columns that sufficiently retain HPK oligomers if present
(Amicon Ultra 0.5-ml centrifugal filters, 100K NMWL).
Each retentate (20l) was directly loaded on aMini-protein
TGX stain-free gel (4–15%; Bio-Rad); the 10% glycerol in
the storage-incubation buffer was sufficient for loading the
protein on the gel. After electrophoresis using standard na-
tive electrophoresis buffer (25 mM Tris, 192 mM glycine,
pH 8.3) at 200 V for 35 min, the gels were visualized using a
ChemiDoc MP imaging system (Bio-Rad). The bands were
additionally visualized by Coomassie staining according to
standard procedures.
DLS
A Malvern ZEN 3600 Zetasizer Nano was used for DLS
analyses. Each analysis comprised at least three measure-
ments per sample, with each measurement comprising 100
runs at an average of 34k particle counts/s. The reported av-
erage is the number particle size determination parameter,
which yields the most frequent particle size in the sample
accounting for the intensity fluctuations of larger particles.
The intensity of the particles was computed via Zetasizer
software version 7.01, which applies the Stokes-Einstein
equation to correlate the change in the scattering intensity
and particle movements. For DLS of samples incubated at
varied pHs, each pH buffer alone was first read to ensure
proper signal-to-noise ratios. Noise below 100k counts/s at
the lowest attenuation was considered acceptable to begin
measurements.
Electrophoretic mobility shift analysis (EMSA)
The ErbB2/HER2 synthetic siRNA duplex (50 pmol) was
incubated with 0, 5 or 10 g protein (PB, PBK or HPK) in
50 l 0.1 M HEPES/Optimem I buffer for 20 min at RT
and then subjected to electrophoresis on a 2% agarose gel
(1:1, low-melting agarose/SeaPlaque GTG) in 0.5× Tris–
borate–EDTA buffer. The gel was then stained with ethid-
ium bromide to visualize siRNA and siRNA–protein com-
plexes. Where indicated, isolated particles assembled as de-
scribed in ‘Particle formation’ were incubated with heparin
at various concentrations before gel electrophoresis.
Isothermal calorimetry
Binding kinetics were determined using a Malvern Pana-
lytical MicroCal PEAQ isothermal calorimeter, which as-
sesses heat exchanges resulting from binding or dissocia-
tion by integrating the differential power that is required to
maintain isothermal conditions. Matched buffer into buffer
was assessed before each experiment to confirm that there
was minimal heat exchange under baseline conditions be-
fore adding the analytes to the system. Two microliters of
20 M siRNA solution was injected into 6 MHPK at RT
to yield the molar ratios displayed in the figures.
Electron microscopy
Particles were prepared for transmission electron mi-
croscopy and imaged, as described previously (53), through
the services of the Electron Imaging Center for NanoMa-
chines within the California NanoSystems Institute at
UCLA.
Serum protection assay
Free siRNA alone (60 pmol) or preincubated with HPK
(2 g for 30 min at RT) was incubated in either complete
medium (10% active bovine serum) or whole (100%) non-
heat-inactivated serum at 37◦C for 1 h and then assessed by
agarose gel electrophoresis.
Immunorecognition assays
ELISAs were used to determine the immunorecognition
of HPK by anti-adenovirus serotype 5 (Ad5) antiserum
compared to that for PB. HPK and PB were immobilized
at 4 g/well on an ELISA plate, and serum from Ad5-
inoculated mice was added to each, followed by the de-
tection of captured mouse Ig titers using standard pro-
cedures (44). A sandwich ELISA was used to compare
the immunorecognition of HPK with that of HSi parti-
cles. Specifically, plates were precoated with rabbit anti-Ad5
polyclonal antiserum (ab6982; Abcam) and incubated in
sodium bicarbonate coating buffer (pH 9.2), followed by
a brief wash and blocking using 3% BSA. After washing
with PBS,HPKandHSi particles were incubated overnight,
followed by detection with a mouse anti-RGS-His anti-
body (34660; Qiagen) and anti-mouse horseradish peroxi-
dase (A8924; Sigma-Aldrich). Colorimetric detection and
absorbance measurements at A650 began 15 min after the
addition of TMB (3,3′,5,5′-tetramethylbenzidine) substrate.
The reaction was then stopped by adding 1 N HCl, and
measurements at A450 were acquired.
RNAi assays
To evaluate mRNA silencing in vitro, cells were plated in 96-
well plates 36–48 h before treatment with various concen-
trations of HSi particles in complete medium (30–50 l per
well) with agitation at 37◦C for 4 h and 5% CO2. Complete
medium was then added to a total volume of ∼100 l per
well. For cells receiving siRNA lipoplexes, the siRNAs were
assembled with Lipofectamine RNAiMax reagent (Thermo
Fisher), and cells were treated 24 h after plating in a 96-well
plate, according to the manufacturer’s protocol. Plates were
maintained at 37◦C at 5% CO2 for 48–72 h after treatment,
followed by cell lysis and the collection of RNA for quanti-
tative PCR (qPCR; see below).
To evaluate ErbB2/HER2 protein knockdown by West-
ern blotting, cells were treated with either siRNA lipoplexes
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or HPK-siRNA assemblies in complete medium and incu-
bated for 48 h at 37◦C, after which, the medium was ex-
changed for fresh medium. Ninety-six hours after trans-
fection, ErbB2 levels were analyzed by western blotting.
Lipoplexes were formed by incubating 100 pmol siRNA
with Lipofectamine 2000 in Optimem I according to
the manufacturer’s protocol. HPK-siRNA complexes were
formed by incubating 100 pmol siRNA with 20 g HPK
at a 1:2 or 1:4 (siRNA/protein) molar ratio in 100 mM
HEPES in Optimem I buffer at RT for 20min before adding
to cells in complete medium. The cells were then lysed with
RIPA buffer (150 mM NaCl, 50 mM Tris base [pH 8.0], 1
mM EDTA, 0.5% sodium deoxycholate, 1% NP-40, 0.1%
sodium dodecyl sulfate, 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride, and 1 mMNa3VO4) supplemented
with complete protease inhibitor cocktail. Protein concen-
trations were determined using Bio-Rad protein assay dye
reagent. The cell lysate proteins were separated by 10%
PAGE (25 g of total protein loaded per well), followed by
electrotransfer (140 mA for 2 h) to a nitrocellulose mem-
brane (Hybond-ECL; Amersham Biosciences, Piscataway,
NJ, USA). The membranes were blocked in PBS containing
3% dry milk for 1 h at RT with constant agitation. The ni-
trocellulose was incubatedwith 1g/ml anti-ErbB2/HER2
(Upstate/Millipore, Billerica, MA, USA) diluted in PBS
with milk, agitating at 4◦C overnight. The membranes were
washed twice with water and then incubatedwith secondary
antibody for 1.5 h at RT. Themembranes were washed twice
with water and then with PBS with 0.05% Tween for 3–5
min. The nitrocellulose was rinsed with water 4–5 times and
processed for chemiluminescence.
To evaluate ErbB2/HER2 protein knockdown by im-
munocytofluorescence, complexes containing HPK with
lipoplexes were formed by incubating either 1.5, 5 or 10 g
of HPK with siRNA lipoplexes for a final molar ratio of
1:1:1, 1:2:1 or 1:4:1 (siRNA/HPK/Lipofectamine), respec-
tively. These complexes were formed by incubating HPK
with lipoplexes at RT for an additional 20min after lipoplex
formation, and then the complexes were added to the cells.
Control cells were incubated in 100 mMHEPES/Optimem
I buffer alone, with HPK only, or with siRNA only. Ninety-
six hours after treatment, the cells were fixed and processed
for immunocytofluorescence.
qRT-PCR
RNA was collected with a Promega SV96 kit and comple-
mentary DNA (cDNA) was produced with a Bio-Rad iS-
cript RT Supermix according to the manufacturers’ proto-
cols. cDNA was stored in 10 mM Tris–HCl (pH 8.0), 0.1
mMEDTAbuffer at−20◦Cuntil use. Ribogreen and SYBR
green nucleic acid binding dyes were used to quantify RNA
and cDNA, respectively. The qualities of RNA and cDNA
samples were determined by measuring the A260/A280 ra-
tios. Three samples per group were assayed, each contain-
ing 75 ng cDNA. A TaqMan gene expression assay was
used to perform qPCR, and amplification products were
analyzed using a CFX Connect qPCR system (Bio-Rad).
The primer/probe sequences were as follows: RTF primer,
TCTGGACGTGCCAGTGTGAA; RTR primer, TGCT
CCCTGAGGACACATCA for ERBB2 (accession num-
ber NG007503); luciferase probe set Mr03987587 (Thermo
Fisher) for firefly luciferase (accession number AF093683).
Unless otherwise indicated, data were analyzed using the
Cq method.
Cytotoxicity assay
Cytotoxicity wasmeasured by crystal violet staining, as pre-
viously described (53).
In vivo procedures
All mice were obtained from Charles River Laborato-
ries. All procedures involving mice were approved by the
IACUC (protocol #4796) and were performed in accor-
dance with the institutional and national guidelines for the
care and use of laboratory animals. Data were collected
in a single-blinded fashion, such that the identities of the
treatment groups were unknown to the individual acquir-
ing the measurements. For xenograft models, 6-week-old
female immunodeficient (NU/NU) mice received bilateral
xenograft implants of MDA-MB-435 tumor cells (1 × 107
cells/implant). For immune-competent models, female 6-
week-old BALB/c mice received bilateral mammary fat pad
injections of 4T1-Luc cells (1 × 105 cells/injection). For
bothmodels, mice were randomized at tumor establishment
(≥100–150mm3) into separate treatment groups (n= 5mice
per group). For whole-animal time-course imaging, mice
received single tail vein injections of either siRNA or HSi
(each equating 0.087 mg/kg Cy5-labeled synthetic siRNA,
obtained from Invitrogen). The mice were viewed by multi-
mode optical imaging to detect Cy5 fluorescence intensity,
and images were acquired at various time points after injec-
tion. Images were acquired under constant gain settings to
enable comparisons. The fluorescence contrast between tu-
mor and nontumor regions was acquired by selecting spe-
cific known areas on the mouse images at the various time
points andmeasuring the fluorescence intensities of each re-
gion. The contrast comparisons between tumor and non-
tumor regions in siRNA- and HSi-injected mice were ob-
tained by subtracting the fluorescence intensities for each
time point from the nontumor region from those at tumor
regions for eachmouse. To detect the biodistribution of near
infrared (NIR)-labeled cargo, mice received single tail vein
injections of the reagents equating 1.5 nmol Alexa Fluor
680-labeled siRNA and were imaged ∼4 h later using a
Xenogen IVIS system, followed by tissue harvest and imag-
ing of extracted tissue to acquire average radiance per tissue
area. For therapeutic efficacy studies, the reagents were de-
livered by tail vein injections (0.087 mg/kg siRNA) twice
weekly for 4–6 weeks, and tumor volumes (height × width
× depth) were monitored ∼2–3 times/week under single-
blinded conditions (treatment groups unknown to the in-
dividual acquiring the measurements). At the experiment’s
termination, all animals were sacrificed, and tissues were
collected for follow-up analyses. To assess luciferase silenc-
ing in vivo, mice received a single tail vein injection (0.087
mg/kg siRNA/injection), and mRNA from the tumors was
harvested ∼72 h later.
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Immunogenicity assay
Female BALB/c mice (∼6 weeks; Charles River) received
tail vein injections of HSi-Scr siRNA at 1.5 nmol siRNA
per injection once/week for 4 weeks. Dosages equated 0.5
mg/kg per injection of HPK.Replication-deficient Ad5 was
delivered as a control inoculant at 1.2× 109 PFU/injection.
Serum was collected and 1 × 10−4 dilutions were processed
by ELISA, using either HSi-Scr (5 g/ml, 0.5 g/well) or
Ad5 (5 × 106 PFU/well) as capture antigens. Mouse Ig
was detected using horseradish peroxidase-conjugated anti-
mouse antibody, and ELISAs were performed according to
standard procedures used elsewhere (44). Serial dilutions of
mouse Ig were used as reference antibody titers.
Statistical analyses
Except where indicated, statistical significance was de-
termined by one-way analysis of variance followed by a
Tukey’s post hoc analysis. Statistical significance was set at
0.05. Error bars in figures represent standard deviations un-
less otherwise indicated. Sample sizes were determined by
power analyses of our previous in vitro and in vivo data (54),
which indicated that in vitro sample sizes have 80% power at
the 0.05 significance level to detect a 0.18 difference between
group means in a two-factor ANOVA, and in vivo sample
sizes achieve at least 80% power at the 0.05 significance level
in a repeated-measures ANOVA.
RESULTS
HPK forms HER3-binding capsomeres
The PB serves as the foundational unit of HPK and thus
provided the starting point for examining the architecture
of HPK through computational structural modeling. In its
natural state, the PB protein forms a homopentamer that
normally caps each vertex of the Ad icosahedron (48) (Fig-
ure 1A). We previously constructed a recombinant gene en-
coding the Ad5 PB sequence fused to a carboxy-terminal
decalysine (designated domain IV, for binding nucleic acids)
(Figure 1A and B and Supplementary Figure S1A and C),
producing the modified protein referenced here as PBK
(55). Nondenaturing gel analysis has shown that PBK pen-
tamerizes under native conditions (55).
The HER3-targeted version of this protein, designated
HPK here, results from genetic modification of PBK to in-
clude an N-terminal ligand (domain I) derived from the
minimal receptor-binding region of human heregulin (or
neuregulin)-11 (56) (Figure 1A and B). The HPK gene
construct includes a sequence encoding an oligopeptide
linker (domain II) comprising neutral residues that separate
the targeting ligand and PB (domain III) functional seg-
ments (Figure 1A and B) (56). Structural modeling of HPK
under physiological conditions in solution suggests that the
ligand and PB domains fold independently while remaining
bridged together by an unstructured linker (Figure 1A).
Recombinant expression of HPK yields a product mi-
grating at a molecular weight (MW) of between 90 and 100
kDa under denaturing conditions (Figure 1B) whose pep-
tide identity has been verified through proteomics analy-
sis. Under nondenaturing conditions, a product migrating
between 480 and 720 kDa predominates (Figure 1B), sug-
gesting that HPK oligomerizes in a native environment. In
support, MD simulations show that HPK assumes a stable
pentameric structure during a 100 ns relaxation under phys-
iological conditions (Figure 1C). Pentamerization of HPK
predicts a MW of ∼500 kDa, which closely aligns with the
high-MW species seen with native gel electrophoresis (Fig-
ure 1B). The computer modeling of HPK yields a pinwheel-
like configuration, with each targeting ligand extended in a
splayed position froma central pentameric barrel formed by
the PB domain of each HPKmonomer (21) (Figure 1C and
Movie S1). The central barrel is visible under transmission
electronmicroscopy (Figure 1C) and resembles the ring-like
configuration of viral capsomeres (57). The MD simulation
of HPK suggests that pentamerization is stably maintained
while the extended ligands have a flexible range of move-
ment (Movie S2; image frames shown in Figure 1D). This
observation is supported by measurements taken of both
the outer diameter and pentamer edge length of the central
barrel, which both show that the size is maintained during
the 100 ns relaxation (Figure 1E). In further support, we
found that HPK co-precipitated with soluble recombinant
PB, suggesting that HPK oligomerizes through the PB do-
main (Figure 1F). Together, these findings suggest that the
PB domain drives the stable self-assembly of HPK into pen-
tamers.
Our structural findings of HPK suggest that the ligands
remain solvent exposed and thus should be available for re-
ceptor binding in a protein homo-oligomer. In agreement,
HPK exhibits considerable binding to an immobilized pep-
tide containing the extracellular domain of human HER3,
which is blocked by preadsorption with the peptide in vitro
(Figure 2A) and on HER3-expressing breast tumor cells
(Figure 2B; cell surface HER3 levels shown in Supplemen-
tary Figure S2), confirming the receptor specificity of the
ligand. In further support, HPK preferentially enters cells
expressing high levels of HER3 versus those with low levels
(Figure 2C–E). Specifically, theMDA-MB-435-Br4 (or Br4)
cell line displays cell surface HER3 levels that are signifi-
cantly higher than the parental line, regardless of cell den-
sity (Figure 2C). HPK exhibits concomitantly higher bind-
ing to the Br4 line than the parental line (Figure 2D), as
well as measurably higher uptake at levels reflecting the dif-
ferences in HER3 expression (Figure 2E). These findings
were further validated by demonstrating that the silencing
of HER3 in MDA-MB-435 cells significantly reduced the
binding of HPK (Figure 2F).
The HPK capsomere is endosomolytic and forms a pH-
sensing barrel
Intracellular trafficking of HPK follows a similar pattern as
that of wild-type PB (Figure 3A), which rapidly transits to-
ward the nuclear periphery after cell entry (52,58), similar
to the whole virus (59–61). Subcellular fractionation shows
substantial entry of HPK into cytoplasmic and cytoskeletal
compartments after uptake into HER3-expressing MDA-
MB-435 cells (Figure 3A; relative cell surface HER3 levels
shown in Supplementary Figure S2). These findings com-
pare favorably with those for the wild-type PB, for which
a considerable proportion is internalized to cytoskeletal
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Figure 1. HPK forms soluble capsomeres with flexible ligands. (A) MD model of HPK monomer with functional domains delineated. Schematics show
Ad5 capsid and heregulin proteins, with the PB pentamer (top) and receptor-binding domain of heregulin (bottom) in boxes. Ribbon structures of the
corresponding polypeptide and folded chimera are shown. Each monomer of the PB and the functional domains of the HPK chimeric protein (assigned
numerals I–IV) are delineated by different colors. Schematic below ribbon structure of the chimeric protein represents the folded monomer. (B) Expression
of recombinant chimeric protein. Schematic shows the linear structure of HPK with functional domains delineated (from amino [N] to carboxy [C] termi-
nus): I, targeting ligand; II, oligopeptide bridge composed of the neutral residues, Gly-Gly-Ser-Gly-Gly-Ser or (GGS)2; III, PB; IV, decalysine tail (K10).
Protein gels show electrophoresis of HPK under denaturing (DN) and native (NTV) conditions. (C) MD structure of HPK pentamer. Ribbon model of
HPK is shown as a pentamer with each monomer highlighted by a different color. Side and axial views (from the ‘top’ and ‘bottom’ of the pentamer) are
shown (all sides of rotating pentamer can be viewed in SupplementaryMovie S1). Transmission electron microscopy image of HPK preparation exhibiting
self-assembled capsomere-like structures is shown on the right. EM image is contrast enhanced to highlight structure. (D) MD simulation of pentamer in
solution. The images were captured at sequential time points of the MD simulation (the full simulation can be viewed in Supplementary Movie S2). (E)
MD analysis of pentamer stability in solution. Two order parameters were tracked during MD simulations of the pentameric unit: (i) the diameter of the
pentamer core (red) and (ii) the edge length of the pentameric projection of the core (blue). (F) Binding between PB-derived proteins. Blot shows labeled
PB after co-precipitation with indicated bait protein prebound to nickel resin (shown in duplicates). Input, 5 l of PB alone. (–) nickel resin lacking bait.
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Figure 2. HER3-specificity. (A) ELISA showing binding of HPK to immobilized HER3 peptide; y axis reflects ELISA absorbance normalized by relative
cell number, ‘HER3 block’ indicates HPK was preadsorbed with soluble HER3 peptide before incubating on the immobilized peptide. (B) Detection of
HPK binding to HER3 on individual tumor lines by cell surface ELISA; ‘HER3 block’ indicates HPKwas preadsorbed with a HER3 peptide at equimolar
or 10-fold molar excess concentrations before incubation with cells. (C–E) HER3 expression, receptor binding, and particle uptake in brain metastatic cell
line, MDA-MB-435Br4, in comparison to that in parental cells, MDA-MB-435. (C) Cell surface HER3 levels measured by cell surface ELISA. (D) Binding
of HPK at indicated protein concentrations per well measured by cell surface ELISA. Un, untreated cells; Un, untreated cells; 2◦ Ab, secondary antibody
alone; 1◦+2◦, primary and secondary antibodies. (E) Immunocytofluorescence and laser scanning confocal fluorescence microscopy of indicated cell lines
at indicated time points of HPK uptake. Bars, 20 m; *P < 0.05; **P < 0.01 (n = 3). (F) Effect of HER3 silencing on HPK binding to MDA-MB-435
cells. Micrographs show immunocytofluorescence of HPK and HER3 at ∼24 h after cells received HER3 or scrambled siRNA in comparison to untreated
cells. Graph summarizes the relative levels of cell-bound HPK under HER3-silencing and control conditions. Each data point represents the average from
three independent fields (>500 cells per field) in triplicate wells undergoing each corresponding (HER3 silencing or control) condition. KD, knockdown.
*P < 0.05; **P < 0.01.
and nuclear compartments (similarly to the trafficking of
whole Ad) (59–61) that are otherwise inaccessible with-
out endosomal disruption, while a small proportion was
retained in the membrane fraction (Figure 3A). To inves-
tigate this further, we examined the intracellular traffick-
ing of HPK and assessed whether it accumulated in early
and/or late endosomes. Our findings reveal that during cell
uptake, HPK transiently overlaps with EAA1-labeled early
endosomes but not with RAB7-positive late endosomes-
lysosomes (Figure 3B). Moreover, a diminishing localiza-
tion of internalized HPK with early endosomes accompa-
nied a concomitant increased distribution to non-EEA1
non-RAB7 compartments but no further accumulation in
late endosomes-lysosomes (Figure 3B). These findings sup-
port the exit of HPK from early endosomes, which may be
attributable to the PB domain (on the basis of its functional
roles during Ad infection) (33,52,58); thus, we next investi-
gated whether the capsomere structure contributes to endo-
somolysis.
Structural modeling of both PBK and HPK cap-
someres revealed that the pentameric ring creates a solvent-
accessible pore lined with His and other charged amino
acids, specifically, negatively-charged glutamic (Glu) and
aspartic (Asp) acids that appear to be counterbalanced by
positively-charged lysine (Lys) and arginine (Arg) residues
(Figure 3C and Movie S3). This observation led us to in-
terrogate whether a low-pH environment such as that en-
countered in the endolysosome could lead to protonation
of these residues and induce charge-mediated repellence of
monomers (as depicted in Figure 3D), thus unmasking hy-
drophobic domainsmediating pentamerization (48). On the
basis of the structural models, a pentameric configuration
has a buried surface area of 41 413 A˚2, of which 19 133
A˚2 is hydrophobic (Supplementary Figure S3) and will be
exposed when the pentameric structure breaks into its con-
stituent components. When exposed, these domains could
interact with membrane lipids and destabilize the endolyso-
somal membrane, enabling the penetration of both the PB
and HPK into soluble cell compartments, as observed ear-
lier (Figure 3A). To examine this, we first assessed the pro-
tonation states of all titratable amino acids in the capsomere
barrel of both PBK andHPK using the PropKa server (50).
At a physiological pH of ∼7.0, the Glu and Asp residues
are negatively charged (except five Asp residues, due to their
local environment) and all His residues are neutral, result-
ing in a net −10 charge on the PBK pentamer (Table 1).
At an acidic pH of 5.0 (as encountered in endolysosomes),
30 of the 430 acidic residues (Asp/Glu) and 30 of the 50
His residues become protonated, leading to some neutral
Glu and Asp residues and many positively charged His
residues (Table 1). Hence, a transition from pH 7.0 to pH
5.0 would yield a net +55 change in charge for the PBK
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Figure 3. Cell entry. (A) Internalization and subcellular fractionation. Micrographs show intracellular trafficking of HPK or soluble recombinant PB after
uptake in MDA-MB-435 cells. Side views of cells are shown in xz and yz planes. Bars, 5 m. Western blots show subcellular fractions of MDA-MB-435
cells harvested 1–2 h after uptake probed with an antibody recognizing the PB. NP, no protein (untreated cell lysate); CP, cytoplasm; MB, membrane; NC,
nucleus; CK, cytoskeleton; Ctl, control (protein alone, 5 g). Fractionation controls delineating subcellular compartments include GAPDH (cytoplasmic),
TIM23 (membrane), lamin A (nuclear and cytoskeletal), and -actin (cytoskeletal). (B) HPK trafficking to early and late endosomes. Micrographs show
the time-constrained trafficking of HPK (green) through initial binding (0 min), internalization (30min), and intracellular transit (60 min). Early endosome
marker EEA1 is shown (red) along with late endosome marker RAB7 (magenta). Left bar graph summarizes the percentage of internalized HPK overlap-
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Table 1. Protonation states of titratable amino acids
PBK HPK
pH 7 5 7 5
Arg (+1) 175 175 215 215
Lys (+1) 145 145 250 250
His (+1) 0 30 0 30
His (0) 50 20 55 25
Asp (0) 5 15 0 10
Asp (-1) 170 160 190 180
Glu (0) 0 15 0 20
Glu (-1) 160 145 260 240
Pentamer charge -10 45 15 75
 charge, pentamer +55 +60
pentamer (Table 1). The stability of the HPK pentamer
shown in the MD simulations (Movie S2) indicates that the
titratable residues identified in the PBK pentamer barrel
are retained in HPK capsomeres. Accordingly, these same
residues would undergo charge conversion in the HPK pen-
tamer upon a change in pH from 7.0 to 5.0 (Figure 3E),
while additional residues introduced by the targeting ligand
contribute to an overall pH-mediated +60 shift in charge
(Figure 3E and Table 1).
The location of these charges within the pentamer bar-
rel is likely to cause strong positive charge-mediated re-
pellence of the protein monomers. To test this, we exam-
ined whether HPK undergoes a size shift from oligomers to
monomers under acidifying conditions. Nondenaturing gel
electrophoresis of HPK under neutral conditions showed
the presence of pentamers and higher MW oligomers (Fig-
ure 3F, ‘input’). Size filtration of HPK under defined pH
conditions before electrophoresis enabled us to examine
whether these species were retained with increasing acid-
ification. Whereas pH 7.4 had no effect, reducing the pH
to 5.0 dramatically reduced the presence of pentamers and
oligomers (Figure 3F, ‘5.0’), with a concomitant increase
in monomers (Figure 3G). In further support of this, DLS
measurements showed that a shift from neutral to acidic
pH shifted the size of HPK (as well as PBK) to a smaller
species (Figure 3H). The additional +5 net positive charge
that would occur upon protonation of HPK (compared to
PBK) (Table 1) suggests thatHPKmay possess a higher sen-
sitivity to pH conditions than PBK. In agreement, a broader
set of pH increments enabled us to observe that HPK ex-
hibits a reduction in size at a milder acidity (∼pH 6) com-
pared to that for PBK (∼pH 5) (Figure 3H).
HPK capsomeres assemble with siRNA into serum-stable
multivalent nucleocapsids
Our structural modeling shows that pentamerization of
both HPK and PBK places the polylysine domains of each
monomer at a single face on the pentamer (Figure 4A),
forming a cation-rich surface that should interact strongly
with anionic molecules such as nucleic acids. In support,
the electrophoretic mobility of siRNA is reduced by the
decalysine-containing protein (+K10) in contrast to corre-
sponding protein lacking the decalysine sequence (-K10)
(Figure 4B). The structure of HPK suggests that its bind-
ing to siRNA requires ligand bending toward the PB barrel
to accommodate protein packing into particles (Figure 4C),
which may yield intermediate species of siRNA-bound pro-
tein reflecting multiple conformations during particle as-
sembly. In agreement, titration of HPK onto siRNA results
in multiple electrophoretic species of bound siRNA, with
the higher MW species becoming more prominent as pro-
tein concentration––and hence particle packing––increases
(Figure 4D). These findings are supported by isothermal
calorimetry measurements showing that interactions be-
tween HPK and siRNA are saturable, become less disor-
dered with increasing titration, and occur at a subnanomo-
lar binding affinity (Kd = 270 pM) (Figure 4E).
Isolated complexes exceeding ∼10 nm in diameter yield
spherical particles with hydrodynamic diameters ranging
between 40 and 60 nm (Figure 4F) that constitute a sin-
gle electrophoretic species (Figure 4G). Additional DLS
parameters based on intensity- and volume-weighted dis-
tributions corroborate these findings, and larger species
that would be indicative of aggregates in solution were
not detected (Supplementary Figure S4A). Exposure to
heparin to mimic the anionic environment of the cyto-
plasm (62) facilitated the release of the siRNA payload
(Figure 4G) and enabled the quantification of protein
and siRNA content. Here, heparin-mediated disassembly
yielded a protein/siRNA molar ratio of (4.5–5.5):1, sug-
gesting a stoichiometry of one siRNA molecule per pen-
tameric unit (Table 2). Together, these findings support a
model in which the siRNA21-mer (which bears a net charge
of −44) can neutralize the five K10 tails (net charge of
+50) of the HPK pentamer [(HPK)5], thus preventing elec-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
ping with RAB7 at indicated time points (0, 15, 30 and 60 min) of uptake (n = 8 cells per time point) compared to the percentage of internalized HPK
that does not overlap with RAB7 (non-RAB7). Right graph summarizes the percentage of internalized HPK overlapping with RAB7, EEA1, or neither
(non-EEA1, non-RAB7) marker at early, mid, or late stages of cell entry. Stages are based on percentage of overlap with EEA1. **P < 0.01, comparing
EEA1 overlap; ***P< 0.001, compared to non-RAB7. (C) Ribbon model of PBK. Titratable amino acids are represented by space-filling residues: purple,
Lys/Arg; green, Asp/Glu; red, His. (D) Proposed capsomere dissociation in response to low pH. Schematic shows putative protonation of barrel interior
and dissociation of monomers in response to acidification. (E) Structural modeling of HPK with titratable amino acids highlighted. The pH 7 structure
shows the negatively charged Asp/Glu in red and neutral His residues in green. The pH 5 structure shows the neutral Asp/Glu residues in green and
positively charged His residues in blue. Arrow indicates net gain of positive charges upon protonation, as summarized in Table 1. (F, G) Native PAGE of
HPK after exposure to titrating pH and size retention. Protein gels show electrophoretic mobility of HPK before (input) and after size filtration to isolate
retentates containing oligomeric protein. Samples were loaded onto gels in the same pH buffers in which HPK was incubated before and during filtration.
The gels in panel F show HPK pentamers (p) and oligomers (o) postfiltration in comparison to the starting HPK protein (input) before aliquoting into
pH-adjusted buffers and filtering to isolate species larger than monomers. The gel in panel G shows HPK monomers in nonfiltered samples after incubat-
ing under indicated pH conditions. Graph in panel G summarizes band densities. *P < 0.05; M, high-molecular-weight protein marker. (H) Effect of pH
on average diameters of HPK and PBK. Histograms show sizes measured by DLS after exposure to pH 7 and pH 5 conditions described above. Graph
summarizes average sizes measured by DLS after incubating in indicated pH titrations and represents at least three independent experiments.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz900/5588347 by U
C
LA user on 16 O
ctober 2019
12 Nucleic Acids Research, 2019
Figure 4. Assembly with siRNA into serum-stable nucleocapsids. (A) Space-filling models of PBK and HPK pentamers, showing decalysine sequences
(highlighted in green).MD structures show each pentamer viewed from the ‘bottom.’ The PBKC-terminal residues (Lys581) are indicated. The N-terminal
residues (Met1) are in yellow. The HPK targeting ligands in magenta. (B and D) EMSAs of siRNA after incubation with HPK, PBK, or PB at indicated
concentrations. Figure shows an inverse image of ethidium bromide-stained gel. (C) Schematic of HPK pentamer undergoing hypothetical conformational
changes to accommodate siRNA packaging. Protein domains are colored corresponding to the structure shown in panel A. (E) Binding kinetics of HPK
with siRNA. Binding curve reflects heats recorded by isothermal calorimetry during titration of siRNA into HPK. Recorded heats were integrated to
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Table 2. Protein:siRNA stoichiometry of HSi particlesa
Samplesb
1 2 3 4
siRNA conc (ng/l) 99.01 105.22 94.30 121.30
HPK conc (g/l) 3.1 3.8 3.6 4.1
siRNA (pmol/l) c 7.44 7.91 7.09 9.12
HPK (pmol/l) d 33.70 41.30 39.13 44.57
Molar ratio (HPK:siRNA) 4.5 5.2 5.5 4.9
aParticles were assembled and filtered to isolate high MW complexes as described in
the Methods. To measure siRNA content, particles were disassembled with heparin
followed by exposure to a nucleic acid binding dye (RiboGreen; Thermo Fisher Sci-
entific) and extrapolation of fluorescence measurements against a standard curve of
known siRNA concentrations. Protein content was measured by spectrophotometric
absorbance using the Bradford method (Bio-Rad dye assay).
bSamples and corresponding information on protein and siRNA content were ran-
domly selected from logged stocks of prepared particles.
cBased on approximate MW of 13 300 g/mol.
dBased on approximate MW of 92 000 g/mol.
trostatic repulsion between capsomeres and allowing them
to converge into a spherical particle based on the shape
complementarity of the pentamer units inherited from the
Ad5 viral protein (shown in Supplementary Figure S4B).
We furthermore found through computational structural
modeling (Supplementary Figure S4B) that these intracap-
somere contacts are dominated by polar interactions (hy-
drogen bonds and salt bridges) upon charge neutraliza-
tion of the K10 tails by the siRNA. Whereas the minimum
composition of such a sphere would equate to at least 12
(HPK)5 units [(HPK)60], predicting a diameter of ∼30 nm
based on the atomic structure of HPK (see Supplementary
Methods), the ability to accommodate the siRNA cargo
may require additional pentamers to widen the capsule,
thus yielding a slightly larger diameter, in agreement with
our DLS measurements (Supplementary Figure S4). The
resulting particles––designated HSi––resist destabilization
in serum: exposure of naked siRNA to active serum results
in rapid degradation by serum nucleases, whereas assembly
with HPK protects the siRNA from serum-mediated degra-
dation (Figure 4H).
Taken together, these findings suggest that siRNA be-
comes encapsulated, or encapsidated, byHPKuponHSi as-
sembly, yielding a particle with multivalent ligands. To eval-
uate this functionally, we assessed whether HSi recruited
higher levels of HER3 than HPK alone upon tumor cell
binding and uptake, as depicted in Figure 5A. We observed
that both HSi and HPK caused significant subcellular re-
organization of HER3 upon cell binding, resulting in lo-
calized areas of HER3 convergence compared to that in
untreated cells (Figure 5B). Importantly, the initial recep-
tor binding was performed at a low temperature to pro-
mote ligation but not internalization, thus preventing or
stalling energy-dependent processes, such as the translation
of new HER3 protein. During cell uptake, the overlap of
both HPK and HSi with HER3 increased compared to ini-
tial receptor binding (30 min vs 0 min, Figure 5C), which
might have resulted from an increased recruitment of recep-
tors (including nonligated receptors) to areas of internal-
izing receptor-ligand complexes. However, HER3 showed
significantly higher overlap with HSi than with HPK dur-
ing cell uptake (Figure 5C), corresponding to augmented
HER3 clustering induced byHSi compared to that by HPK
(Figure 5D). Altogether, these findings show that HSi in-
fluences HER3 distribution to a greater extent than HPK
alone upon cell interaction, supporting a particle structure
bearing ligand multivalency.
We also assessed the impact of ligand multivalency on
immune recognition. On the basis of the MD simula-
tion of HPK, the ligands are in a solvent-exposed po-
sition on the capsomere (Movie S2) that may partially
mask the PB domain from immune recognition (Figure
5E, schematic). In agreement, immunorecognition by poly-
clonal anti-Ad5 antiserum was significantly lower for HPK
than for PB (Figure 5E). Assembly of the HPK capsomere
into HSi particles should add further ligand multivalency
to the resulting structure and presumably further hinder
immunorecognition of the PB (Figure 5F, schematic). In
agreement, immunorecognition by polyclonal anti-Ad5 an-
tiserum was lower for assembled particles (HSi) than for
capsomeres (HPK) (Figure 5F). This same antiserum other-
wise recognizes the PB domain under denaturing conditions
(52,55,56) (Supplementary Figure S1B).
HPK nucleocapsids facilitate HER3-directed siRNA delivery
in vivo
HPK showed improved siRNA delivery to tumors in vivo
when we compared the spatiotemporal distribution of sys-
temic HSi to that of naked siRNA labeled with Cy5 (Figure
6A–C). As shown in Figure 4H, naked siRNA was quickly
degraded in serum, whereas HPK afforded protection from
serum nucleases; hence, the fluorescence signal measured
from naked siRNAmay reflect the Cy5 label liberated from
degraded siRNA. In comparison, the Cy5 distribution after
HSi delivery exhibited higher tumor-to-nontumor contrast
at each time point (Figure 6B) and higher tumor retention
than naked siRNA at 24 h after injection (Figure 6A and
C). Naked siRNA delivery resulted in similar Cy5 distribu-
tions in the liver and tumors, whereas HSi accumulated in
tumors at a level that was >10-fold higher than in the liver
and other nontumor tissue (Figure 6C). A closer look at the
tissues showed that HER3 levels were considerably lower in
the livers, where it was sparsely distributed, than in tumors
(Figure 6D). At highermagnification, HER3 showed strong
overlap with claudin 5, which delineates tight junctions in
the liver (Figure 6E). The few liver-associated particles that
were detected were restricted to these sites, with little to no
observable particle entry into the liver parenchyma (Figure
6E).
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
derive H and Kd values. (F) Particle shape and size. Panels show transmission electron microscopy of HSi particles (top) and average hydrodynamic
diameter of HSi particles in comparison to individual components (siRNA, HPK) measured by DLS (bottom). EM images were contrast enhanced to
highlight structure. (G) EMSA after ultrafiltration of complexes. Ethidium bromide-stained agarose gel shows relative electrophoretic migration of free
siRNA or HSi particles (∼500 ng siRNA per lane) after isolation by ultrafiltration. (H) Stability of HSi in active serum. Electrophoresis and ethidium
bromide staining of siRNA after incubating in active (non-heat-inactivated) serum under the indicated conditions followed by gel electrophoresis. (–) or
(+) HPK, lacking or including siRNA preincubation with HPK, respectively, before exposure to serum.
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Figure 5. Contribution of ligand multivalency to cell interactions and immune shielding. (A) Multivalent interaction with HER3. Schematic illustrates
how the multivalency of HSi may induce receptor clustering in cells. (B) Spatiotemporal localization of HER3 (ErbB3) during HPK or HSi uptake in
MDA-MB-435 cells, shown by laser scanning confocal microscopy of cells fixed after indicated treatment and processed for immunocytofluorescence.
Bars, 10 m. (C) Ratios of HER3 overlap with HPK or HSi to total fluorescence at the indicated time points during cell uptake. *P < 0.05; **P < 0.01
versus respective 0-min timepoint (n = 4). (D) Quantification of the HER3 fluorescence intensity. Bars are the mean integrated densities of fluorescence
for HER3 and symbols show individual data points for each treatment. Un, untreated cells. *P < 0.05 versus Un (n = 3). (E, F) Immunorecognition by
anti-Ad5 capsid antiserum. (E) Schematic of antibody interactions with PB versus HPK (left). ELISA probed with Ad5 antiserum using PB and HPK as
antigens (right). (F) Schematic comparing HPK and particle (HSi) interactions with Ad5 antiserum (left). ELISA probed with Ad5 antiserum using HPK
and HSi as antigens (right). *P < 0.05; **P < 0.01 (n = 3).
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Figure 6. Biodistribution and tumor targeting. (A) Live animal imaging of mice bearing bilateral MDA-MB-435 tumors captured at sequential time points
after single tail vein injections of Cy5-HSi or free Cy5-siRNA (each equating 0.087 mg/kg Cy5-labeled synthetic siRNA). Schematic shows orientation
of images, with tumors indicated by arrows. (B) Fluorescence contrast comparisons between tumor and nontumor regions of mice injected with siRNA
alone versus HSi from panel A. *P < 0.05 at all time points (n = 10). (C) Quantification of HSi tissue distributions compared with that of siRNA alone
24 h after single tail vein injections. *, P<0.05 versus all other samples (n = 3). Tu, tumor; Li, liver; Ki, kidney; Lu, lung; Sp, spleen; Mu, muscle; H,
heart. (D, E) Comparison of tumor versus liver distributions after systemic particle delivery. (D) Immunohistofluorescence images showing HER3 staining
(green) of tumor and liver specimens from the same tumor-bearing mice ∼2.5 h after systemic particle delivery (blue, nuclei). Graph summarizes the
quantified differences in HER3 levels between tumor and liver tissues. *P < 0.05 (n = 5). (E) Higher magnification of liver specimens showing labeled
particle in comparison to HER3 and claudin 5 staining. Lower panels show magnification of delineated region in upper panels. IF, immunofluorescence;
BF, brightfield. (F) Tumor distribution in mice bearing both HER3-high (JIMT1) and HER3-low (231) tumors. Images show NIR signal acquisition from
mice after receiving single tail vein injections of particles. (G) Imaging of harvested tumors from mice shown in panel F. Graph shows the quantification
of NIR-labeled particles in each tumor. (H) Immunohistofluorescence imaging and quantification of HER3 levels on respective tumor types. *P < 0.05;
**P < 0.01 (n = 4).
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To further evaluate the tumor-homing capacity of HPK
nucleocapsids in vivo, we assessed delivery in mice bearing
two different human breast tumors with high and low/no
HER3 expression (JIMT1 and 231, respectively) (Figure
6F). Systemically delivered nucleocapsids preferentially ac-
cumulated (2–3-fold) in JIMT1 compared to 231 tumors
(Figure 6G), corresponding to the 2–3-fold differences in
HER3 levels (Figure 6H).
HPK targets RNAi to HER3-expressing tumor cells
To examine how HPK affects siRNA efficacy, we evaluated
the gene-silencing activity of siRNAs delivered by HSi in
comparison to commercial lipofection. As ErbB2 knock-
down can induce apoptotic tumor cell death (63,64), we
used a siRNA against the ErbB2/HER2 tyrosine kinase in
several human tumor cell lines expressing both HER2 and
HER3. We first examined the efficacy of mRNA knock-
down with siRNAs delivered nonspecifically by cationic
liposomes. Importantly, mRNA was extracted for qPCR
before cells exhibited signs of cytotoxicity. The minimum
siRNA concentration eliciting maximum ErbB2 mRNA
reduction via lipoplex delivery occurred at ∼5 nM (Fig-
ure 7A). Similarly, HSi-mediated delivery of ErbB2 siRNA
(HSi-ErbB2) significantly reduced ErbB2 mRNA levels
compared to HSi-mediated delivery of a scrambled siRNA
sequence (HSi-Scr) at HPK/siRNA molar ratios of at least
4:1 (Figure 7B); a lower molar ratio was not as effective.
Importantly, HSi performed better than commercial lipo-
fection under physiological conditions mimicking systemic
delivery (i.e. in complete medium at 37◦C with constant ag-
itation) (Figure 7C). HSi substantially reduced ErbB2 pro-
tein levels in several types of human tumor cell lines, includ-
ing those of breast, ovarian, and melanoma origins (Fig-
ure 7D). HPK also augmented lipofection-mediated deliv-
ery of ErbB2 siRNA, further reducing ErbB2 protein lev-
els in comparison to lipofection alone (Figure 7D). We also
compared human tumor-derived cells with high (HER3+
MDA-MB-435 cells) or low/undetectable (HER3− MDA-
MB-231 cells) cell surface HER3 expression but with com-
parable levels of ErbB2 in the cell cytoplasm (Figure 7E
and F). Commercial lipofection reduced ErbB2 similarly in
both tumor lines, whereas HSi reduced ErbB2 only in the
HER3+ cells (Figure 7G), demonstrating the specificity of
HSi-mediated delivery.
To further validate the efficacy of HSi, we measured
the survival of these cells treated with various amounts of
siRNA. The survival of HER3+ but not HER3− tumor cells
was reduced by HSi in a concentration-dependent manner
(Figure 8A). By contrast, the survival of both cell types
was reduced by siRNAs delivered by commercial lipofec-
tion (Figure 8B). Intravenous delivery (via tail vein) of HSi
in mice bearing human xenografts of HER3+ tumors sig-
nificantly reduced tumor growth rates (Figure 8C), corre-
sponding to a substantial reduction of ErbB2 (Figure 8D).
Nonsilencing particles (H-NS) and nontargeted siRNA de-
livery (NT-Si) had no effect on tumor growth (Figure 8C)
or ErbB2 level (Figure 8D). One tumor that did not show
a change in volume after HSi-ErbB2 treatment (HSi unre-
sponsive [UnR]; tumor volume not shown) still exhibited
a considerable reduction in ErbB2 (Figure 8D) and sub-
Table 3. Serum analyte panel (average ± SD) from treated mice (N = 5)
Mock HSi H-NS
ALT (U/l) 18.25 ± 2.28 25.10 ± 3.65 23.25 ± 5.80
AST (U/l) 59.00 ± 18.34 50.33 ± 11.38 61.50 ± 39.22
BUN (mg/dl) 22.00 ± 1.41 18.33 ± 2.21 18.75 ± 1.48
CREAT (mg/dl) 0.13 ± 0.04 0.07 ± 0.05 0.10 ± 0.07
stantial cell loss inside the tumor core compared to that in
control mice receiving saline (Figure 8E). Blood chemistries
showed no significant changes in liver and kidney function
between HSi- and mock (saline)-treated groups (Table 3).
To evaluate immunogenicity, we examined sera fromnon-
tumor-bearing immunocompetent mice after exposure to
HSi or control inoculants. Naı¨ve (preimmune) mice had a
significant pre-existing serum response to the control anti-
gen, Ad5, and no significant reactivity to HSi (Figure 9A).
A repeat inoculation of HSi at 10 times the therapeutic dose
given to tumor-bearing mice did not produce detectable
HSi-binding antibodies, whereas Ad5 treatment generated
virus-binding antibodies that did not cross-react with HSi
(Figure 9B). After four inoculations, HSi did not result in a
significant generation of reactive antibodies in comparison
to that in mock (saline)-treated mice (Figure 9C).
We also examined siRNA function in an immune-
competent environment using a syngeneic model of HER3+
tumors. To do so, we first needed to verify whether HPK
cross-reacts with mouse HER3. A sequence comparison of
the ligand (i.e., heregulin)-binding regions of mouse and
human HER3, specifically, extracellular domains I and II
(65), showed a high level of amino acid sequence identity
(94%) (Figure 9D). The 4T1 mouse mammary tumor line
is a well-established model of triple-negative breast cancer
(66), and we found that these tumor cells express consid-
erable levels of HER3 on the cell surface (Supplementary
Figure S2). HPK bound to these cells in a manner that was
competitively inhibited by preadsorption to human HER3
peptide (Figure 9E). HPK was also taken up into 4T1 cells
upon binding (Figure 9F). Together, these findings indicate
that HPK cross-reacts with both mouse and human HER3.
As 4T1 cells lack ErbB2 expression, we used cells stably
expressing luciferase (4T1-Luc) and examined the efficacy
of HSi for delivering luciferase siRNA (HSi-Luc). HSi-Luc
significantly reduced luciferase luminescence (Figure 9G)
and mRNA expression (Figure 9H) in cultured 4T1-Luc
cells. As further in vivo validation, a single systemic adminis-
tration of HPK delivering a labeled oligoduplex probe pref-
erentially accumulated in orthotopic 4T1 tumors compared
to nontumor tissue and in comparison to the probe alone
(Figure 9I). Systemic delivery also yielded considerable re-
duction of tumor luminescence (Figure 9J) corresponding
to a significant reduction in Luc mRNA expression (Fig-
ure 9K) in tumors from 4T1-Luc xenografts. Altogether,
the results demonstrate that HSi-mediated delivery of siR-
NAs is effective and targeted to cells with high expression
of HER3.
DISCUSSION
The results presented here show that HPK is a HER3-
targeted biocarrier for systemic homing of RNAi to
HER3-expressing tumors––including triple-negative breast
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Figure 7. Comparison with commercial transfection. (A, B) qPCR of ERBB2 mRNA isolated from MDA-MB-435 cells after in vitro treatments with
cationic liposomes (A) or HSi (B) delivering ERBB2 or scrambled siRNA. *P < 0.05; **P < 0.01 versus corresponding HSi-Scr treatments (n = 4). (C)
Western blotting (anti-ErbB2 and anti-actin) of MDA-MB-435 cell lysates collected 96 h after indicated treatments. Lipo, Lipofectamine; siRNA-Scr,
scrambled siRNA; siRNA-ErbB2, anti-ErbB2 siRNA. (D) Immunocytofluorescence of ErbB2 protein in SKBR3 human breast cancer cells or SKOV3
human ovarian cancer cells after delivery of ErbB2 or scrambled (Scr) siRNAby lipoplexes or targeted complexes. LSi, lipoplexed siRNA;HLSi, lipoplexed
siRNA with 2.5, 5 or 10 g HPK added equating 1:1:1, 1:2:1 or 1:4:1 siRNA/HPK/liposome, respectively. The 1:2:1 ratio is shown for SKOV3. Graph
summarizes quantification of ErbB2 immunocytofluorescence normalized per cell. *P < 0.05 versus respective untreated cells unless otherwise indicated
(n = 4). (E) Flow cytometry of MDA-MB-435 (top) and MDA-MB-231 (bottom) tumor cells based on cell surface HER3 levels. Red, untreated; blue,
HER3 antibody treated. (F) Comparison of ErbB2 immunocytofluorescence in MDA-MB-231 (HER3−) and MDA-MB-435 (HER3+) cells, showing
proportions of internal and cell surface ErbB2. **P< 0.01 (n= 4). (G) Comparison of ErbB2 knockdown between HER3+ (MDA-MB-435) and HER3−
(MDA-MB-231) cells. ErbB2 levels are expressed as internal ErbB2 immunocytofluorescence normalized by cell number. *P < 0.05; **P < 0.01, versus
untreated cells (n = 4).
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Figure 8. Delivery in ErbB2 xenograft model. (A, B) Survival of HER3+ (MDA-MB-435) and HER3− (MDA-MB-231) tumor cells after in vitro exposure
to titrating concentrations of HSi-ErbB2 (A) or liposomes alone (Lipo), lipoplexed siRNA (Lipo-siRNA), siRNA alone, HPK alone, or HSi, each given in
a single treatment (B). *P< 0.05 versus corresponding untreated (Un) cells (n= 3). (C) Growth rates of MDA-MB-435 xenograft tumors in mice receiving
tail vein injections of HSi (delivering ErbB2 siRNA, equating 0.087 mg/kg siRNA per injection) or indicated controls. Mock, saline injected; H-NS, nonsi-
lencing particles; NT-Si, nontargeted siRNA. *P< 0.05; **P< 0.01 (n= 5). Significances refer to end-point tumor volumes at the time of sacrifice. Images
show representative control (mock) and HSi-treated mice at the time of sacrifice for comparison of the tumor sizes. (D) ErbB2 immunohistofluorescence
(green) of the tumor tissue extracted frommice in panel C. Histograms show quantifications of ErbB2 immunohistofluorescence intensity. (E) Hematoxylin
and eosin staining of tumor specimens from control and HSi-treated mice. HSi unresp, tissue from tumor that appeared unresponsive (based on tumor
volume) to HSi treatment.
tumors––in vivo. The combination of MD simulations and
functional assays revealed that HPK forms endosomolytic
capsomeres that assemble with siRNA into serum-stable
nucleocapsids whose ligand multivalencies hinder immune
recognition while facilitating robust receptor interaction
and cell uptake.We also showed that HPK cross-reacts with
both human and mouse HER3 and mediates the delivery
of RNAi to both human and mouse HER3-expressing tu-
mors in vivo while avoiding off-target toxicity and immuno-
genicity. The therapeutic benefit of this application was
demonstrated by the delivery of ErbB2 siRNA in a HER3-
expressing tumor model, resulting in a reduced tumor bur-
den compared to that in experimental controls.
Effective transfer of siRNA requires delivery into the cy-
toplasm and hence a mechanism for penetrating the plasma
membrane. Several lines of evidence indicate that HPK pro-
vides this function. First, the basic foundation upon which
HPK was built is the Ad5 capsid PB, which was function-
ally shown to bear cell-penetrating properties (33,52,58) de-
spite an unknownmechanism of membrane destabilization.
Intracellular trafficking studies of subgroup C viruses, in-
cluding Ad2 and Ad5 which share high sequence identity
(67), have shown that the viral particles attach to dyneinmo-
tors after endosomal escape and are ferried along intact mi-
crotubules as naked particles toward the nuclear periphery
(61). These particles appear as discrete puncta undergoing
minus-end directed movement in fluorescence-based imag-
ing studies (68,69). Our studies showed that recombinant
soluble Ad5 PB recapitulates the trafficking of the whole
virus and relies on similar microtubule-dependent transit
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Figure 9. Delivery to triple-negative breast cancer cells in an immune-competent model. (A–C) ELISA of BALB/c mouse serum to detect antibodies
generated against indicated antigens (HSi and Ad5) after 2× /week dosing for 4 weeks. (A) Ig titer measurements from preimmune serum using HSi and
Ad5 as ELISA antigens. **P < 0.01 (n = 14). (B) Ig titer measurements from sera of HSi- and Ad5-inoculated mice after two inoculations, using HSi
and Ad5 as ELISA antigens. **P < 0.01 versus all other combinations of serum and antigen (n = 6). (C) Ig titer measurements at sequential time points
comparing sera from HSi- and mock (saline)-inoculated mice. Arrows indicate time points of inoculations (n = 6). (D) Amino acid sequence alignment
of domains I–II (amino acids 20–239, heregulin-binding domain) of human and mouse HER3. Blue residues indicate amino acid differences. (E) Binding
of HPK to 4T1 mouse triple-negative breast cancer cells. *P < 0.05 versus HPK alone (n = 3). (F) Uptake and intracellular trafficking of HPK in 4T1
mouse mammary tumor cells. Side views of cells are shown in xz and yz planes. Bars, 8 m. (G) Luminescence measured from 4T1-Luc cells at indicated
time points after exposure to HSi-Luc. Measurements are shown normalized to delivery of a scrambled siRNA sequence (HSi-Scr). *P< 0.05 (n= 3). (H)
qPCR of luciferase mRNA isolated from 4T1-Luc cells at 48 h after treatment with HSi-Luc or HSi-Scr. *P < 0.05 versus each corresponding HSi-Scr
concentration (n = 3). (I) Biodistribution of NIR-labeled oligoduplex probe alone (–HPK) or delivered by HPK (+HPK). H, heart; Ki, kidney; Li, liver;
Lu, lung; Sp, spleen; Tu, tumor. *P < 0.05 versus (–HPK) and all other tissues (n = 3). (J) Luminescence imaging of representative immune-competent
mice bearing orthotopic 4T1-Luc tumors before (pre) and at∼30 h after (post) a single tail vein injection of HSi-Luc or siRNA alone (0.087 mg/kg siRNA
per injection). (K) qPCR of mRNA isolated from 4T1-Luc tumors at 72 h after a single tail vein injection of HSi-Luc or HSi-Scr (0.087 mg/kg siRNA per
injection). Ctl, control (saline injected) treatment. *P < 0.05; **P < 0.01 (n = 4).
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through the cytoplasm (52). As the cytoskeleton connects
organelles andmediates transport between subcellular com-
partments, the cytoskeletal trafficking machinery is an ef-
fectivemeans bywhich viruses can deliver nucleic acid cargo
to intracellular targets (70). By contrast, free nucleic acids
injected into the cytoplasm exhibit little movement in the
cytosolic milieu and become targeted by cytosolic nucleases
(71,72), which would likely impede gene-silencing strategies
targeting mRNA transcripts.
The cytoskeletal association of viral-derived proteins like
the PB is thus an expected and advantageous feature af-
ter endosomal escape. Here, we observed a significant as-
sociation of HPK with the cytoskeleton, similar to that for
the PB and whole Ad (52,59). We also observed that after
transiently overlapping with early endosomes, the majority
of internalized HPK avoids late endosomes-lysosomes and
accumulates intracellularly, becoming increasingly disen-
gaged from both early and late endosomal compartments.
These findings are consistent with our previous studies
showing that HPK (also known as HerPBK10) (44) delivers
anionic molecules––including nucleic acids and sulfonated
corroles that would otherwise be repelled by the negatively
charged cell membrane––to the cell cytoplasm after endocy-
tosis into acidifying vesicles (51,54). Our previous findings
show that removal of the PB domain prevents cytoplasmic
entry of anionic corroles (51), suggesting that the PB do-
main of HPK mediates the endosomolytic process neces-
sary for siRNA delivery. In support of this, we and others
have demonstrated that recombinant soluble PB enters the
cell cytoplasm after endocytic uptake (52,58). However, the
mechanism by which this takes place was unknown. Our
studies here suggest that the capsomere barrel formed by
the PB domain of HPK acts as a pH-sensing pore whose
protonation triggers disassembly and exposure of buried
domains. This is evidenced by the identification of titrat-
able histidines and other charged residues lining the bar-
rel that considerably increase the local positive charge upon
protonation at low pH. This is predicted to induce charge-
mediated repellence of constituent monomers, and in agree-
ment, we show here that lowering the pH reduces HPK
oligomers to lower MW species consistent with monomers.
Our analyses also support previous crystal structure stud-
ies of the PB showing that the domains mediating pen-
tamerization of the PB are largely hydrophobic (48). Hence,
their exposure upon disassembly of the capsomere enables
binding to the endosomal membrane, possibly leading to its
destabilization. Indeed, both HPK and wild-type PB enter
nonmembrane subcellular compartments, with some slight
differences. HPK is predicted to undergo higher protona-
tion than PBK on the basis of the analysis of titratable
residues. In agreement, these proteins exhibited different
sensitivities to an acidified environment, withHPK showing
a response (a reduction in particle size) to a slightly milder
pH environment (pH 6–7) than PBK (pH 5–6). If this tran-
sition is indeed associated with endosomolysis, these find-
ings predict that HPK should escape from early endosomes
(pH 6–6.5), whereas wild-type PB would escape from more
mature endolysosomes (pH 5–5.5). This would be consis-
tent with our previous studies using the fluorescence life-
time shift of attached corroles to determine that HPK tran-
sits through a slightly acidifying vesicle compartment before
cytosolic entry (51). Overall, these findings open the door
to further studies interrogating the relationship of the cap-
somere structure to pH-triggered subcellular dynamics and
have generated two important findings. First, we have be-
gun to uncover how the PB mediates endosomolysis. These
findings have implications regarding the widely used Ad de-
livery vector (60,68,73), for which the efficiency of cell pen-
etration has been attributed to the PB (58,74,75). An un-
derstanding of the mechanism by which the PB disrupts the
membrane may pave the way for strategies to modulate this
activity in both viral and nonviral vectors and thereby in-
fluence potential therapeutic applications. Second, our find-
ings show evidence of HPK-cellular interactions mediated
in part by the PB domain that promote the delivery of
siRNA cargo to the appropriate subcellular environment.
The barrel structure formed by self-assembled HPK
places the nucleic acid binding moieties at one end of the
barrel, promoting the electrostatic attraction of siRNA
at this same barrel fac¸ade and thus the capsomere pack-
ing around the siRNA cargo. Indeed, electron microscopy
showed that HPK exposed to siRNA forms spherical
particles comprised of what appear to be multimerized
capsomeres. These capsomeres surround (encapsidate) the
siRNA, providing protection from serum nucleases upon
assembly with HPK. Whereas nucleic acids, including un-
modified siRNA, are rapidly degraded in serum (76), the
protection seen after assembly suggests that our payloads
arrive at target tissues largely intact. Our structural mod-
eling predicts a minimum nucleocapsid composition of 12
HPK pentamers, in agreement with the dodecahedral struc-
tures known to form from recombinant soluble Ad3 PB
protein (32). However, the encapsidation of siRNA may
require additional capsomeres to accommodate the cargo,
thus forming spheres with diameters that may be slightly
larger than that expected for (HPK)60. The multimerization
of capsomeres should create ligand multivalency if indeed
the ligands remain exposed on the nucleocapsid particle. In
support, we found that the assembled particles taken up by
tumor cells clustered HER3 to a greater extent than free
HPK. These findings agree with the notion that capsomere
assembly with the siRNA cargo results in exposure and dis-
play of the targeting ligands over the surface of the assem-
bled particle. This, in turn, may prevent immunorecognition
of the PB domain through steric hindrance. Accordingly,
the HPK capsomere alone partially reduced polyclonal an-
tibody recognition of the PB, which was further reduced by
assembly into nucleocapsids. These findings suggest that the
PB domain becomes immunologically masked when assem-
bled into particles, by being buried in the nucleocapsid, be-
ing blocked by exposed ligands, or both. Immune masking
of the PB via steric hindrance by other capsid proteins on
the assembled Ad capsid has been described before (77,78)
and could apply here via the heregulin ligands extending
from the particle surface. An advantage of this is the poten-
tial to appear as a naturally occurring ligand in the body,
thus providing a stealth approach to targeting. This may
account for the low immunogenicity observed here, though
further comparisons––to free HPK or PB, perhaps––may
be warranted in future studies. Notably, our immunogenic-
ity studies entailed inoculation with the particle at 10 times
the dosage used for therapeutic efficacy, equating to a num-
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ber of PB molecules (∼1013) roughly an order of magnitude
higher than for the control inoculant, Ad5 (∼1012). Hence,
the conditions for testing immunogenicity were appropri-
ately rigorous.
To properly assess the ability of HPK to deliver siRNA to
mouse tumors in an immunocompetent model, we first con-
firmed thatHPK cross-reacts withmouseHER3, whichwas
expressed at considerable levels on the surfaces of mouse
4T1 tumors (triple-negative mammary tumors). These find-
ings correspond to the high sequence identity between the
ligand binding regions of mouse and human HER3. This
cross-reactivity not only enabled us to examine tumor tar-
geting in an immune-competent environment but also raises
the potential clinical relevance of our existing findings in
xenograft models: HPK particles preferentially accumu-
lated in human-derived HER3-overexpressing tumors de-
spite the cross-reactivity with endogenous mouse HER3.
This is a consideration that may be overlooked with the
use of xenograft models in preclinical testing of targeted
therapies that are specific to human antigens, which limits
the extent to which tumor targeting can be appropriately
interpreted. In many such cases, ‘tumor targeting’ may be
more validly interpreted as ‘human-antigen targeting.’ Ad-
ditionally, although the potential leakiness of tumor vas-
culature, known as enhanced permeability and retention
(79,80), can contribute to tumor-preferential accumulation
in vivo, we show here thatHPKparticles preferentially accu-
mulated in the highHER3-expressing tumor rather than the
low HER3-expressing tumor present on the same mouse.
Taken together with the HER3 binding specificity of HPK,
its blocking in vitro by HER3 peptide, overlap with HER3
on cell and tissue specimens, and the comparatively higher
HER3 expression on tumor tissue, these studies strongly
suggest that tumor targeting by HPK is directed predom-
inantly by ligand-receptor binding to HER3-dense cells.
The therapeutic efficacy tested in this study was limited
to the delivery of siRNA against ErbB2. This gene was
a convenient target to prove the principle that HPK can
deliver siRNA to HER3-expressing tumors and because
ErbB2 amplification is frequently associatedwithHER3 co-
expression (20). Additionally, we wanted to use a siRNA se-
quence known to affect the growth of such tumors (63,64).
Although we were unable to use this same siRNA to test
therapeutic efficacy in an immunocompetent triple-negative
breast cancer model, we showed the proof of principle
that HPK particles delivered RNAi for a reporter gene, lu-
ciferase, in thismodel. Ongoing studies are investigating po-
tential siRNA species that could be therapeutically useful
for this model and may rely on upstream regulators whose
silencingwould have considerable impact on tumor progres-
sion (81,82). Additional ongoing studies are investigating
the influence of HPK itself on therapeutic impact. In par-
ticular, the seemingly modest but transient attenuation of
tumor growth in mice by ‘empty’ HPK particles (i.e., H-
NS) may be consistent with the temporary attenuation of
HER3 signaling observed at early time points after recep-
tor binding in our recent study (21), which in turn may be
supported by the robust sequestration of HER3 by HPK
particles observed in the present study, as well as the sub-
sequent PB-mediated disruption of endosomes. Additional
mechanistic understanding of cellular interactions of HPK
and the PBmay enable further designmodifications tomod-
ulate potency.
The field of oligonucleotide delivery joins other fields in
the ongoing concern regarding reproducibility and rigor in
experimental design, execution, and analysis (83,84). Thus,
we carefully conducted our experiments with rigor and
transparency. Examples of this can be seen in our efforts
to keep our studies unbiased by appropriately randomiz-
ing our animal subjects before treatment regimens, acquir-
ing data in a blinded fashion, and sharing our complete
methodology and all sequences to enable replication of ex-
perimental procedures. Where possible, we used alternative
supplementary assays to validate our findings and ensure
that interpretations were appropriate. Furthermore, to en-
sure reproducibility, we performed statistical power analy-
ses a priori to determine appropriate sample sizes and re-
peated experiments independently in triplicates at the mini-
mum.We hope these efforts undertaken at a more open and
rigorous experimental design contribute to the translation
of this and similar technologies into helpful novel therapeu-
tics.
In conclusion, this study showed that the systemically ad-
ministered HER3-targeted biocarrier, HPK, delivers RNAi
to HER3-expressing tumors, with low to undetectable off-
target toxicity and immunogenicity. We showed that HPK
forms endosomolytic capsomeres that encapsidate siRNA
into serum-stable particles with ligand multivalencies con-
tributing to reduced immune recognition and robust re-
ceptor interaction, thus promoting stealth-like activity.
Our demonstration that HPK recognizes both human and
mouse HER3 enables testing in both xenograft and syn-
geneic immunocompetent tumor models. Additionally, this
cross-reactivity provides a rigorous testing ground for as-
sessing targeting to HER3-dense tissue. The overexpression
of HER3 in a growing array of tumor types (1–13) indicates
that theHPK-mediated targeting described here could be of
broad potential benefit. The association of HER3 with re-
sistance to growth factor inhibition (1,2,7,14–18) suggests
that HPK-mediated delivery of alternative cargo such as
siRNA provides a possible strategy for addressing tumors
with few to no clinical options, especially since HER3 bears
no inherent kinase activity that can be blocked by conven-
tional inhibitors (19,20). Hence, the delivery of siRNA ther-
apeutics through HER3-mediated targeting may widen the
options available for treating such cancers.
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